PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think it is middle Or end of q3 when we are looking at bigger changes. If fda approval comes in and they move on to their plan on selling in other countries that’s when I fell the market will really take to this a la tern, web, or pyc or for those of you who may remember Fitbit years back. But this is just my opinion and I am Happy for someone to bash it cos it is speculation. Let’s see
yes can't agree with draft at all. the market cap is miniscule and medical AI is the emerging market at the moment. Big things to come here
I don't think market cap is toppy at a all. The recently acquired Imaging Biometrics has added great value to this share.
im sure they ll get approval - im out at the moment - who th ehell is the seller and down 7% today and market cap seems a bit toppy in my opinion for where these guys are right now. Look at this objectively - dont fall in love with a share.
FDA news any day now. DYOR
https://esut18.uroweb.org/exponential-technological-development-poses-questions-future-surgeons/ Positive comments at the Urology conference about the adoption of AI in general
right now - off to Italy
However, the Prime Minister has now doubled the government�s contribution to the programme, which, when added to an extra �25m offered by Cancer Research UK, means the fund will initially be worth �65m a year. https://www.independent.co.uk/news/uk/home-news/government-brain-cancer-funding-dame-tessa-jowell-40-million-65-research-cure-a8350231.html The government will double its investment in brain cancer research to �40m a year in honour of former cabinet minister Dame Tessa Jowell. Plans unveiled are set to boost funding for studies into tumours and provide British patients with more treatment options after the Labour peer lost her battle with the disease on Saturday.
to sell now. News could land at any point
Nice find.
Envoi AI now PACS compliant and strategic partner with UK company, baltantly going to take our IB and SC algorithms. https://www.envoyai.com/blog/envoyai-terarecon-and-insignia-partner-to-bring-artificial-intelligence-to-united-kingdom-customers. Cambridge, MA � May 10th, 2018 � EnvoyAI today announced a new integration with Insignia Medical Systems� InSight PACS to provide AI-enhanced imaging workflows to customers. For initial launch in the UK, this integration provides best-of-breed, curated AI content available on the EnvoyAI platform within the PACS environment at multiple integration points. These include AI results viewing directly within the PACS viewer, as well as within the already established Insignia integration with TeraRecon. EnvoyAI is the spinout formed by a 2017 TeraRecon acquisition of McCoy Medical Technologies. TeraRecon�s longstanding partnership with Insignia is further strengthened with the synergies between EnvoyAI�s platform and TeraRecon�s latest advanced visualisation offerings. The integrations with EnvoyAI and TeraRecon allow hospitals to customize their AI portfolio based on algorithms they can test and consume from within their Insignia PACS, including the utilisation of each hospital�s own internally developed algorithms. Jon Hall, Chief Technology Officer, Insignia Medical Systems shared, �Integrating to the EnvoyAI platform allows Insignia to more quickly and broadly execute on our goal of providing the most advanced functionality on the market to our end users. The integration provides instant access to premium AI directly as part of a cohesive end-user experience - expanding how we add value for our customers within a single, powerful interface.� The EnvoyAI platform readies the Insignia InSight PACS for the launch of any AI application � starting with the AI content already available on the EnvoyAI Exchange. With recent growth, the EnvoyAI Exchange now offers a total of 53 products from 22 partners, of which 10 have already achieved US FDA-clearance. The partnership creates added potential for future workflow integrations to TeraRecon�s iNtuition advanced visualisation solution already promoted by Insignia, as well as TeraRecon�s new NorthStar AI-results viewer for advanced physician interactions. Maria Proud-Levitas, Regional Sales Manager for TeraRecon (UK) said, �Working closely with Insignia for over 5 years has created a very clean and powerful offering for our customers. Building on that trust, we now look forward to delivering tools that take UK healthcare boldly into the future.� Steven Rothenberg, MD and Chief Medical Officer of EnvoyAI stated, �The Insignia PACS integration makes the widespread use of AI an immediate reality for clinicians across the UK; allowing for the most rigorous data security protocols with on-premise installations. EnvoyAI is keen on bringing AI to clinicians i
now presenting in SPain, Portugal, and other European countries, So clearly we are going to keep getting contract RNSS here.
Nice RNS. This is one hospital in Greece. They want one the tumour software an have paid for it although your guess is as good as mine as to how much. Then there's Stonechecker and hospitals in India, China, the US (when FDA granted) and the UK. Massive worldwide market. But this has got the ball rolling and should help to keep the traders at bay to a certain extent as others could drop at any minute. Haven't worked out my target just yet but I'm excited. GLA
Anyone got views on value of the deal??? Stonechecker has a clear pricing strategy anyone any idea on the member of the family???
will be REWARDED. Trevor Brown doesnt play games here
I think we will get at least 10 more RNS with sales and contracts and regularly - agree IB is a massive COUP here. I think the MMs are struggling here and deliberately trying to show they wont move this up - but unfortunately for them they will be forced to move this and rapidly.
Imaging Biometrics seems like a bit of a coup for the company, much more deals planned i presume. Nice little bonus on the side
Great to see some buys coming in. FDA approval pretty close so hopefully should see a steady sustAinable climb up to June.
a grand in here early doors, been doing pretty well timing wise of lat on AIM. Hopefully this will be another riser :)
IB Software Chosen by St. Savvas Anti-Cancer and Oncology Hospital Solution will be used to image brain tumours and assess treatment response Imaging Biometrics�, LLC ("IB"), a subsidiary of Flying Brands Limited (LON:FBDU), announced today that the General Anti-Cancer and Oncological Hospital of Athens "St. Savvas", Athens, Greece has installed its full suite of IB Software to help assess treatment response for patients with brain tumours.Amongst the IB software to be used will be IB Rad Tech. IB Rad Tech is a software engine that leverages the core processing libraries of other IB products and further streamlines the workflow. For example, the approach used to generate IB's standardised fractional tumor burden (sFTB) maps relies on the robust perfusion magnetic resonance imaging (p-MRI) available in IB Neuro, and a patented image intensity "standardisation" algorithm incorporated in IB Delta Suite. Exclusive to IB, standardisation enables quantitative and automated inter- and intra-study comparison, resulting in the application of precision/personalised medicine. Dr. Vasileios Κ. Katsaros MD, PhD, Head of the Department of MRI and Neuroradiology, in General Anti-Cancer and Oncological Hospital of Athens "St. Savvas", Clinical and Research Associate, Department of Neurosurgery, University of Athens, General Hospital of Athens "Evangelismos" and Clinical and Research Affiliate, Department of Neuroradiology, University College of London (UCL), as well as co-founder of the Hellenic Neuro-Oncology Group (HENOG) said, "The sooner you can assess if a brain tumour patient is responding to a given therapy, the better the outcome for the patient. IB's tools provide additional information which quantifies the true tumour burden in a repeatable and streamlined manner. This information has the potential to impact the best clinical practice concerning treatment management decisions and could also be used as a discussion aide with patients." Dr. Katsaros added, "It is critical to know if a change in an imaging biomarker accurately represents a change in tumour growth or response to treatment. Without it, surgeons, radiotherapists and oncologists may require more tests or require more time to follow-up the patients and to know, with confidence, that a treatment protocol is effective." ABOUT General Anti-Cancer and Oncological Hospital of Athens "St. Savvas" Founded in 1935, the Greek Cancer Institute is a tertiary public hospital in the service for oncological patients from all over the Greece. From 1940s, there were four oncological departments, five out-patient clinics and four scientific laboratories. In 1945 (after the end of World-War II), the hospital began again to operate under normal conditions with the addition, to the already two existing, of one more Radiotherapy department, while the Microbiological and Radiology Department were modernised, a t
Means there is demand for the software and that it can be successfully installed. The ball is well and truly rolling.
Definitely the start for this to shine, software is now installed and much more to come.
I think this is the start FDA next then sit back and watch the SP rise.
Time to sit back and watch these sales coming pouring in. Gonna be a good summer
Would like an Rns in the morning......just to complement my happiness....lol